skip to content
Primary navigation


Drug - Cuvposa  (Glycopyrrolate Oral Solution [Shionogi Pharmaceuticals]

January 2018


Patient has severe drooling caused by a neurologic disorder and cannot take glycopyrrolate as the tablet formulation. Supporting documentation must be provided at the time of request.

FDA approved indication

Cuvposa (glycopyrrolate) Oral Solution is indicated to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.

Cuvposa reduces drooling by lowering the volume of saliva produced.


Glycopyrrolate tablets are available as 1 mg and 2 mg tablets. Costs of these tablets are $0.55 and $0.98, respectively. Cuvposa is provided as a liquid formulation of glycopyrrolate. The cost differential between tablet and liquid formulation, if based on the maximum daily dose, exceeds $1,500 per month.

Cuvposa dosing and administration

Initial dose titration Max dose
Recommended dose 0.02 mg/kg  TID increments of 0.02 mg/kg every 5-7 days 0.1 mg/kg TID not to exceed 
Doses range from 1.5 to 15 mL per dose and are dependent on child’s body weight and tolerance.

Oral glycopyrrolate should be dosed at least one hour before or two hours after meals. The presence of high fat food reduces the oral bioavailability of oral glycopyrrolate if taken shortly after a meal.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top